Legal & General Group
CYT

Legal & General Group’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Legal & General Group’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,122
Closed -$8K – 3706
2022
Q1 		$8K Buy
2,122
+1,340
+171% +$7.63K ﹤0.01% 3458
2021
Q4 		$9K Hold
782
– – ﹤0.01% 3482
2021
Q3 		$14K Buy
+782
New +$14.6K ﹤0.01% 3389

Other funds holding CYT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Legal & General Group's CYT Position: Q2 2022 in Review

Legal & General Group sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q2 2022, closing a stake of 2,122 shares — an estimated $8K sold.

Legal & General Group first reported a position in CYT in Q3 2021 and held it in 3 quarters. The position peaked at $14K in Q3 2021. 45 funds tracked by Wall St. Rank hold CYT as of Q2 2022.

  • Legal & General Group reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Legal & General Group sold 2,122 Cyteir Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $8K.
  • Legal & General Group first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q3 2021 and held it in 3 quarters.
  • Legal & General Group's Cyteir Therapeutics, Inc. Common Stock position peaked at $14K in Q3 2021.
  • 45 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Legal & General Group's 13F filing for Q2 2022, filed 22 Aug 2022.